Mizuho raised the firm’s price target on HCA Healthcare to $345 from $310 and keeps a Buy rating on the shares. The analyst believes HCA is well positioned to drive revenue and EBITDA growth in 2024, driven by continued solid demand and improved managed care yield due to regulatory changes. The firm says the two-midnight rule could add 3%-4% to the company’s annual adjusted EBITDA estimates.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on HCA:
- HCA Healthcare price target raised to $345 from $320 at Truist
- HCA Healthcare price target raised to $322 from $308 at RBC Capital
- HCA Healthcare price target raised to $330 from $280 at Deutsche Bank
- HCA Healthcare price target raised to $354 from $338 at Leerink
- HCA Healthcare price target raised to $330 from $315 at Oppenheimer
